Noninvasive preimplantation genetic testing for aneuploidy exhibits high rates of deoxyribonucleic acid amplification failure and poor correlation with results obtained using trophectoderm biopsy

ObjectiveTo validate a commercially available noninvasive preimplantation genetic testing for aneuploidy (niPGT-A) assay by investigating the following: prevalence of deoxyribonucleic acid (DNA) amplification failure with niPGT-A; factors affecting and frequency discordant results between niPGT-A traditional aneuploidy.DesignProspective cohort studySettingAcademic-affiliated private practicePatient(s)One hundred sixty-six blastocysts their surrounding culture media from couples undergoing in vitro fertilization July 2019 May 2020 were analyzed.Intervention(s)Blastocyst-stage spent samples underwent using kit that used whole-genome modified multiple annealing looping-based cycle protocol followed next-generation sequencing. Preimplantation trophectoderm (TE) biopsies was performed targeted sequencing.Main Outcome Measure(s)The primary outcome to achieve an interpretable result niPGT-A. Factors DNA also assessed. Discrepancies TE biopsy analyzed, clinical outcomes evaluated.Result(s)Deoxyribonucleic failures observed 37.3% (62/166) samples. With biopsy, no embryos exhibited failure. Embryos shorter duration exposure evidence whole-chromosome on displayed high rates Of 104 both available, discordance noted 42 cases (40.4%). Three classified as aneuploid based progressed successful delivery.Conclusion(s)The among samples, virtually precluding applicability its current form. To aneuploidy. Prospective study Academic-affiliated practice One analyzed. Blastocyst-stage The evaluated. Deoxyribonucleic delivery.